Backing neededThe UK university is working with novel messenger RNA technology, as are Pfizer and Moderna, but with a self-amplifying feature aimed at inducing immunity with a much smaller dose.
The team would consider carrying out a large international trial elsewhere if it can gain backing from a group such as the Coalition for Epidemic Preparedness Innovations, and expects to make a decision on such a study by March, he said.Despite key philanthropic and government support, “it’s been impossible to move at the same speed" as the big players, he said.Imperial had planned to begin larger trials by the end of 2020, targeting potential approval by the middle of this year.